Abstract: A magnetic closure system for HVAC filter grilles has at least one magnet coupled to the HVAC filter grille, the at least one magnet positioned so as to be interposed between the HVAC filter grille and an inner frame for receiving the HVAC filter grille, the magnet abutting both the filter grille and inner frame so as to magnetically couple the HVAC filter grille to the inner frame; and at least one handle on the exterior surface of the filter grille.

Abstract: A magnetic closure system for HVAC filter grilles has at least one magnet coupled to the HVAC filter grille, the at least one magnet positioned so as to be interposed between the HVAC filter grille and an inner frame for receiving the HVAC filter grille, the magnet abutting both the filter grille and inner frame so as to magnetically couple the HVAC filter grille to the inner frame; and at least one handle on the exterior surface of the filter grille.

Abstract: An actuator assembly for a welding gun is provided that has at least three positions in the example. The actuator assembly includes separate working and retract actuators. The working actuator includes a working rod movable between first and second positions. The retract actuator includes a retract rod independently movable relative to the working rod between third and fourth positions. The retract actuator is external to and non-concentrically arranged relative to the working actuator in the example shown. Actuation of the working and retract actuators is coordinated to provide at least three positions while enabling the actuators to be changed or modified independently from one another. A latching device is configured to selectively interlock the working and retract actuators to one another automatically in response to movement the working rod from the first position to the second position.

Abstract: An actuator assembly for a welding gun is provided that has at least three positions in the example. The actuator assembly includes separate working and retract actuators. The working actuator includes a working rod movable between first and second positions. The retract actuator includes a retract rod independently movable relative to the working rod between third and fourth positions. The retract actuator is external to and non-concentrically arranged relative to the working actuator in the example shown. Actuation of the working and retract actuators is coordinated to provide at least three positions while enabling the actuators to be changed or modified independently from one another. A latching device is configured to selectively interlock the working and retract actuators to one another automatically in response to movement the working rod from the first position to the second position.

Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which ?7 nAChR is known to be involved.

Abstract: The present invention relates to compositions and methods to treat diseases or condition with an ?7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.

Abstract: This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.

Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF, receptors, including human CRF, receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

Abstract: The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1 receptors.

Abstract: The present invention provides substituted pyrazinone derivatives of Formula I that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

Abstract: The present invention relates to quinazolinone compounds of formula (I): 1

Abstract: Described are novel N-acylated heterocycle derivatives having affinity for serotonergic receptors. These compounds and their enantiomers, diastercoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.